Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Pathos AI, Inc.
Marengo Therapeutics, Inc.
Novartis
Steba Biotech S.A.
Revolution Medicines, Inc.
Advanced Accelerator Applications
Life Molecular Imaging SA
Arno Therapeutics